EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Engineering low-endotoxin lipid A in a double auxotroph Pseudomonas aeruginosa to develop safer whole-cell vaccines

Víctor Fuentes-Valverde, Patricia García, Ana Candela, Rebeca Santamarina-Fernández, José Avendaño-Ortiz, Emma Martínez-Alonso, Marina Oviaño, Rafael Cantón, Jesús Arenas, Miriam Moscoso, Germán Bou

Frontiers in Cellular and Infection Microbiology · 2026

DOI: 10.3389/fcimb.2026.1840122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Víctor Fuentes-Valverde und 10 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Microbiología Clínica and Grupo de Investigación en Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Ho…. Hauptthemen laut MEDLINE: Lipid A, Pseudomonas aeruginosa, Pseudomonas Infections, Pseudomonas Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Pseudomonas aeruginosa is a highly adaptable Gram-negative bacterium causing severe respiratory infections, particularly in vulnerable populations. The rise of antimicrobial resistance highlights the urgent need for effective vaccines. We previously developed a live-attenuated vaccine candidate, PAO1 Δ murI Δ alr Δ dadX , a genetically stable double auxotrophic strain that exhibited dose-dependent reactogenicity upon intranasal administration in mice, likely due to lipid A component of lipopolysaccharide (LPS).

Methods

To reduce LPS-associated toxicity while preserving immunogenicity, we engineered novel strains by inactivating genes involved in lipid A biosynthesis ( htrB1 , htrB2 ) or modification ( pagP , pagL ). Lipid A structural modifications were confirmed by MALDI-TOF MS. Mutants were evaluated for Toll-like receptor 4 (TLR4) activation, virulence attenuation, and their ability to induce immune responses and protection in an acute pneumonia model.

Results

All engineered strains displayed modified lipid A structures. Mutations in htrB1 and htrB2 reduced TLR4 activation and significantly attenuated virulence following intraperitoneal challenge in mice. Inactivation of pagL resulted in minimal attenuation, whereas pagP inactivation led to marked attenuation without altering TLR4 activation. In the acute pneumonia model, all mutants elicited robust systemic and mucosal immune responses, and conferred strong protection, despite transient weight loss following intranasal administration.

Discussion

Targeted lipid A modification represents an effective strategy to reduce in vitro reactogenicity while preserving immunogenicity in live-attenuated P. aeruginosa vaccine candidates. Although further optimization may minimize residual in vivo effects, these findings support the potential of engineered strains as vaccine candidates for preventing respiratory infections caused by P. aeruginosa .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lipid APseudomonas aeruginosaPseudomonas InfectionsPseudomonas VaccinesAnimalsVaccines, AttenuatedToll-Like Receptor 4MiceDisease Models, AnimalVirulenceAntibodies, BacterialFemaleGenetic EngineeringMutationToll-Like Receptor Agonists

Stichwörter der Autor:innen

Pseudomonas aeruginosaauxotrophyhumoral immunitylipopolysaccharidelive-attenuated vaccinesprotective efficacy

Substanzen

Lipid AVaccines, AttenuatedToll-Like Receptor 4Pseudomonas VaccinesAntibodies, BacterialToll-Like Receptor Agonists

Autor:innen und Institutionen

  • Servicio de Microbiología Clínica and Grupo de Investigación en Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, Universidade da…
  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
  • Department of Research, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
  • Proteomics Unit, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
  • Unit of Microbiology and Immunology, Faculty of Veterinary, University of Zaragoza, Agroalimentary Institute of Aragon, Zaragoza, Spain.

Zitieren

APA

Fuentes-Valverde, V., García, P., Candela, A., Santamarina-Fernández, R., Avendaño-Ortiz, J., Martínez-Alonso, E., Oviaño, M., Cantón, R., Arenas, J., Moscoso, M., & Bou, G. (2026). Engineering low-endotoxin lipid A in a double auxotroph Pseudomonas aeruginosa to develop safer whole-cell vaccines. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1840122

Vancouver

Fuentes-Valverde V, García P, Candela A, Santamarina-Fernández R, Avendaño-Ortiz J, Martínez-Alonso E, et al. Engineering low-endotoxin lipid A in a double auxotroph Pseudomonas aeruginosa to develop safer whole-cell vaccines. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.1840122

BibTeX
@article{FuentesValverde2026,
  author = {Fuentes-Valverde, Víctor and García, Patricia and Candela, Ana and Santamarina-Fernández, Rebeca and Avendaño-Ortiz, José and Martínez-Alonso, Emma and Oviaño, Marina and Cantón, Rafael and Arenas, Jesús and Moscoso, Miriam and Bou, Germán},
  title = {Engineering low-endotoxin lipid A in a double auxotroph Pseudomonas aeruginosa to develop safer whole-cell vaccines},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  doi = {10.3389/fcimb.2026.1840122}
}
Kostenlos starten →